All Stories

  1. Adsorption represents a critical challenge in the quantification of free 25-hydroxyvitamin D3
  2. Living Together, Loving Apart: Health, Sexuality and Relationships in Middle‐Aged and Older Men in Europe
  3. A novel model to study the impact of gender-affirming therapy on bone in young male mice
  4. Testosterone Therapy in Adult Males with Hypogonadism
  5. Age-Stratified Reference Ranges for Directly Measured Serum Free Testosterone in Community-Dwelling and Healthy Men
  6. OC54 - Role of steroid hormone-binding proteins on the bioactivity of 11-oxygenated androgens
  7. Letter to Editor from Yeap et al: “Endogenous sex steroid hormones, sex hormone-binding globulin, and risk of all-cause and cause-specific mortality: A systematic review and dose-response meta-analysis of prospective cohort studies”
  8. The 36th ENTIS (European Network of Teratology Information Services) conference abstracts, September 11th–14th, 2025, Thessaloniki, Greece
  9. The hormonal regulation of men’s sexual desire, arousal, and penile erection: recommendations from the fifth international consultation on sexual medicine (ICSM 2024)
  10. Variability in SHBG assays and the effect thereof on calculated estimates of free testosterone
  11. Cardiovascular safety of testosterone therapy—Insights from the TRAVERSE trial and beyond: A position statement of the European Expert Panel for Testosterone Research
  12. LOW 25-HYDROXY-VITAMIN D3 CONCENTRATIONS ARE ASSOCIATED WITH SEXUAL SYMPTOMS IN MIDDLE-AGED AND OLDER MEN
  13. ASSESSMENT OF MALE ANDROGEN EXPOSURE: A SURVEY ON MEASUREMENT AND REPORTING OF TOTAL TESTOSTERONE, SEX HORMONE-BINDING GLOBULIN, AND FREE TESTOSTERONE IN CLINICAL LABORATORIES ACROSS EUROPE
  14. Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses
  15. Determination of Androgen Bioactivity by an In Vitro Assay During Pubertal Transition in Healthy Boys
  16. Association between pubertal timing and bone and body composition in young adult men
  17. A survey on measurement and reporting of total testosterone, sex hormone-binding globulin and free testosterone in clinical laboratories in Europe
  18. No longer to be ignored: Hypophosphatemia following intravenous iron administration
  19. Sociodemographic, lifestyle, and medical factors associated with calculated free testosterone concentrations in men: individual participant data meta-analyses
  20. Hypogonadotropic Hypogonadism as First Presentation of the Severe Neuroendocrine Disorder Caused by RNF216
  21. Use of calculated free testosterone in men: advantages and limitations
  22. Male hypogonadism: pathogenesis, diagnosis, and management
  23. Vitamin D status in children
  24. The Effect of Endurance Exercise on Semen Quality in Male Athletes: A Systematic Review
  25. Evidence-based definition of hypoprolactinemia in European men aged 40–86 years: the European male ageing study
  26. Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men
  27. Comprehensive vitamin d analysis: LC-MS/MS profiling of eight vitamin D metabolites for enhanced biochemical evaluation of vitamin D (PATHO)physiology in the clinical laboratory
  28. (234) TEMPORAL EVOLUTION IN TESTOSTERONE MEASUREMENTS AND DOSES OF TESTOSTERONE REPLACEMENT THERAPY REIMBURSED BY THE BELGIAN HEALTHCARE SYSTEM BETWEEN 2013 AND 2019
  29. Insulin-like peptide 3 (INSL3) as an indicator of leydig cell insufficiency (LCI) in Middle-aged and older men with hypogonadism: reference range and threshold
  30. SHBG Gene Polymorphisms and Their Influence on Serum SHBG, Total and Free Testosterone Concentrations in Men
  31. APHRODITE criteria: addressing male patients with hypogonadism and/or infertility owing to altered idiopathic testicular function
  32. Impact of hyperprolactinemia on sexual function
  33. Does testosterone influence the association between sleep and frailty in men: results from the European Male Aging Study
  34. Changes in bone and mineral homeostasis after short-term androgen deprivation therapy with or without androgen receptor signalling inhibitor – substudy of a single-centre, double blind, randomised, placebo-controlled phase 2 trial
  35. Hyponatremia, hypernatremia and impairment of functional, psychological and sexual domains
  36. Testosterone Restores Body Composition, Bone Mass, and Bone Strength Following Early Puberty Suppression in a Mouse Model Mimicking the Clinical Strategy in Trans Boys
  37. Number of CAG repeats and mortality in middle aged and older men
  38. Factors Associated With Circulating Sex Hormones in Men
  39. Sarcopenia‐defining parameters, but not sarcopenia, are associated with cognitive domains in middle‐aged and older European men
  40. The effect of testosterone treatment on bone mineral density in Klinefelter syndrome: A retrospective cohort study
  41. Implementation of a care pathway based computerized order entry system streamlines test ordering and offers tools for benchmarking clinical practice
  42. Effects of treatment for diabetes mellitus on testosterone concentrations: A systematic review
  43. The Leydig cell biomarker INSL3 as a predictor of age-related morbidity: Findings from the EMAS cohort
  44. Role of sex hormone-binding globulin in the free hormone hypothesis and the relevance of free testosterone in androgen physiology
  45. Reproductive hormone levels, androgen receptor CAG repeat length and their longitudinal relationships with decline in cognitive subdomains in men: The European Male Ageing Study.
  46. Bone health in ageing men
  47. Association of age, hormonal, and lifestyle factors with the Leydig cell biomarker INSL3 in aging men from the European Male Aging Study cohort
  48. The number of androgen receptor CAG repeats and mortality in men
  49. Inactivation of AR or ERα in Extrahypothalamic Neurons Does not Affect Osteogenic Response to Loading in Male Mice
  50. Binding affinity affecting SHBG SNPs do not majorly affect calculated estimates of free testosterone
  51. Erectile dysfunction predicts mortality in middle-aged and older men independent of their sex steroid status
  52. Calcifediol (25OH Vitamin D3) Deficiency: A Risk Factor from Early to Old Age
  53. Sex Steroid Actions in the Male
  54. Associations of Serum Testosterone and Sex Hormone–Binding Globulin With Incident Cardiovascular Events in Middle-Aged to Older Men
  55. Lower serum testosterone concentrations are associated with a higher incidence of dementia in men: The UK Biobank prospective cohort study
  56. The impact of androgen deprivation therapy on bone mineral density in men treated for paraphilic disorder: A retrospective cohort study
  57. Aging Men With Insufficient Vitamin D Have a Higher Mortality Risk: No Added Value of its Free Fractions or Active Form
  58. Inflammatory markers are associated with quality of life, physical activity, and gait speed but not sarcopenia in aged men (40–79 years)
  59. Self-Reported Shorter Than Desired Ejaculation Latency and Related Distress—Prevalence and Clinical Correlates: Results From the European Male Ageing Study
  60. Novel model to study the physiological effects of temporary or prolonged sex steroid deficiency in male mice
  61. Testosterone Reduces Body Fat in Male Mice by Stimulation of Physical Activity Via Extrahypothalamic ERα Signaling
  62. Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy
  63. Serum Testosterone is Inversely and Sex Hormone-binding Globulin is Directly Associated with All-cause Mortality in Men
  64. Sociodemographic, lifestyle and medical influences on serum testosterone and sex hormone–binding globulin in men from UK Biobank
  65. High serum FSH is not a risk factor for low bone mineral density in infertile men
  66. Free 25-hydroxyvitamin D, but not free 1.25-dihydroxyvitamin D, predicts all-cause mortality in ageing men
  67. Neoplasia in Turner syndrome: a retrospective cohort study in a tertiary referral centre in Belgium
  68. Early effects of androgen deprivation on bone and mineral homeostasis in adult men: a prospective cohort study
  69. High serum FSH is not a risk factor for low bone mineral density in infertile men
  70. Androgens In Men Study (AIMS): protocol for meta-analyses of individual participant data investigating associations of androgens with health outcomes in men
  71. Estrogen receptor alpha signaling in extrahypothalamic neurons during late puberty decreases bone size and strength in female but not in male mice
  72. Nutritional rickets: Historic overview and plan for worldwide eradication
  73. Vitamin D Binding Protein: A Historic Overview
  74. Aromatase inhibitors and selective estrogen receptor modulators: Unconventional therapies for functional hypogonadism?
  75. Bone mineral density is preserved in men with idiopathic infertility
  76. Testicular vein sampling can reveal gonadotropin-independent unilateral steroidogenesis supporting spermatogenesis
  77. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects
  78. Endogenous testosterone supports spermatogenesis even in the absence of gonadotrophins: evidence from a case report
  79. Free Testosterone Reflects Metabolic as well as Ovarian Disturbances in Subfertile Oligomenorrheic Women
  80. Symptomatic androgen deficiency develops only when both total and free testosterone decline in obese men who may have incident biochemical secondary hypogonadism: Prospective results from the EMAS
  81. Endogenous testosterone supports spermatogenesis even in the absence of gonadotrophins: evidence from a case report
  82. EAA clinical guideline on management of bone health in the andrological outpatient clinic
  83. Glycemia but not the Metabolic Syndrome is Associated with Cognitive Decline: Findings from the European Male Ageing Study
  84. Effects of sex hormone-binding globulin (SHBG) on androgen bioactivity in vitro
  85. Sex hormone-binding globulin regulation of androgen bioactivity in vivo: validation of the free hormone hypothesis
  86. Natural history, risk factors and clinical features of primary hypogonadism in ageing men: Longitudinal Data from the European Male Ageing Study
  87. Testosterone Treatment in Older Men
  88. Low Free Testosterone Is Associated with Hypogonadal Signs and Symptoms in Men with Normal Total Testosterone
  89. Evaluation of cognitive subdomains, 25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D in the European Male Ageing Study
  90. Lower bone turnover and relative bone deficits in men with metabolic syndrome: a matter of insulin sensitivity? The European Male Ageing Study
  91. Androgen Deficiency Exacerbates High-Fat Diet-Induced Metabolic Alterations in Male Mice
  92. Low free testosterone is associated with hypogonadal signs and symptoms in men with normal total testosterone levels: results from the European Male Ageing Study
  93. Development of and Recovery from Secondary Hypogonadism in Aging Men: Prospective Results from the EMAS
  94. Low free testosterone is associated with hypogonadal symptoms in men with normal total testosterone levels: results from the European Male Ageing Study
  95. Workshop Abstracts (ECTS/IBMS 2015)
  96. Associations Between Sex Steroids and the Development of Metabolic Syndrome: A Longitudinal Study in European Men
  97. What Determines the Difference in DNA Binding Between the Androgen and the Glucocorticoid Receptors?
  98. Androgens and estrogens in skeletal sexual dimorphism
  99. Sensitive routine liquid chromatography–tandem mass spectrometry method for serum estradiol and estrone without derivatization
  100. Late-Onset Hypogonadism